Sarepta released three‑year follow‑up data for Elevidys (delandistrogene moxeparvovec) suggesting durable functional benefits versus external historical controls. Company analyses show widening differences on motor function measures between treated patients and matched controls over two to three years, and Sarepta says the gap becomes statistically significant at three years. The results come after a turbulent year that included safety questions, label restrictions and patient deaths; Sarepta’s leadership has shifted communications to emphasize long‑term efficacy. Analysts flagged the data as positive but noted commercial recovery will hinge on translating efficacy narratives into prescriber uptake amid lingering safety concerns.